Moreover, a daily dosage of 320 mg of anthocyanin capsules administration resulted in a decrease in mRNA expression of NLRP3 inflammasome components (caspase-1, IL-1β, and IL-18) in PBMCs and the plasma levels of IL-1β and IL-18 in NAFLD patients when compared with the controls [61]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.